Citations

Clear

9383 citation(s) found for "Thomas, PS".

Exploring Access to Care in Zimbabwe Using the 3‐Delay Model
Green, Katerina J. , Matinhira, Naboth, Vallecillo, Tissiana , Arya, Priya , Katiro, Munyaradzi , Nyamurowa, Tafadzwa , Douse, Dontre’ M. , Wiedermann, Joshua P. , Vallecillo, Tissiana , Arya, Priya , Candelo, Estephanía , Green, Katerina , Jain, Amiti

Mayo Clinic

Laryngoscope Investigative Otolaryngology | February 14, 2025 | Volume: 10 | Issue: 1 | Pages: No page available

10.1002/lio2.70091 | PMID 39958943 Get It

ABSTRACTObjective(s)We aim to identify the diversity of barriers to care for otolaryngology‐head and neck surgery patients in Harare, Zimbabwe.MethodsInterviews were conducted at four general otolaryngology clinics in Harare in October 2022.The patient population included children and adults presenting to either government or private clinics. Via interpreter, six standardized questions were discussed with each patient. Survey responses were used to categorize patients into one or more of three types of delays: (1) deciding to seek care, (2) reaching the appropriate healthcare facility, and (3) receiving adequate care after reaching that facility.ResultsForty‐six patients participated in this survey. The average time from problem presentation to treatment in this population was 16.3 months. Twenty‐six percent of patients experienced more than one type of delay. The most common type of delay was Type 3 (67%). Many of these patients reached appropriate facilities but could not receive timely treatment due to lengthy wait times. Type 1 delays affected 35% of patients. Notable causes were fear of doctors, preference for traditional healing, or ignorance to a treatable problem. Type 2 delays were also reported in 37%, commonly due to long distance and time to travel and insufficient finances for these journeys.ConclusionsENT patients in Zimbabwe experience a myriad of delays to receiving appropriate care. Systemic issues, including backlogged surgical lists, convoluted referral patterns, and poor transportation infrastructure, are significant contributors to patient delays. The 3‐delay model is useful for identifying barriers to care for future efforts to improve patient access to safe and affordable surgical care.Level of EvidenceLevel VI.
Comparative outcomes of arteriovenous malformations treatment in eloquent versus non-eloquent brain: A multicenter study with propensity-score weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Aslan, Assala , Tjoumakaris, Stavropoula I, Ogilvy, Christopher S. , Başkaya, Mustafa K. , Kondziolka, Douglas, Sheehan, Jason P. , Riina, Howard A. , Abushehab, Abdallah, Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Ataoglu, Cagdas , Keleş, Abdullah , Muram, Sandeep , Sconzo, Daniel , Rezai, Arwin, Alwakaa, Omar , Park, Min S. , Erginoğlu, Ufuk , Sen, Rajeev , Griessenaur, Christoph, Burkhardt, Jan‐Karl , Starke, Robert M., Sekhar, Laligam N., Altschul, David , Haranhalli, Neil , McAvoy, Malia , Zeineddine, Hussein A. , Abla, Adib A. , Atallah, Elias , Rosenwasser, Robert H. , Stapleton, Christopher J. , Koch, Matthew, Srinivasan, Visish M. , Bulsara, Ketan R., Kim, Louis J. , Pukenas, Bryan , Smith, Edward R. , Alaraj, Ali , Patel, Aman B. , Notarianni, Christina , Lawton, Michael T. , Guthikonda, Bharat , Salim, Hamza , Dmytriw, Adam A , Levitt, Michael R , Chen, Peng R , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Abla, Adib , Altschul, David J , Ogilvy, Christopher S , Alwakaa, Omar , Keles, Abdullah , Erginoglu, Ufuk , Smith, Edward , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Dmytriw, Adam A. , Naamani, Kareem El , Abdelsalam, Ahmed , Kumbhare, Deepak , Essibayi, Muhammed Amir , Tos, Salem M , Mantziaris, Georgios , Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Sekhar, Laligam N. , Levitt, Michael R. , Gooch, Michael Reid , Koch, Matthew J. , Blackburn, Spiros , Kim, Louis J. , Choudhri, Omar , Mosimann, Pascal J , Aziz‐Sultan, Mohammad Ali , Savardekar, Amey Rajan , Cuellar, Hugo , Morcos, Jacques J. , Jabbour, Pascal

Mayo Clinic

International Journal of Stroke | February 14, 2025 | Volume: 20 | Issue: 7 | Pages: 852-863

10.1177/17474930251323503 | PMID 39948730 Get It

Background: Arteriovenous malformations (AVMs) are complex vascular anomalies with a high risk of hemorrhage and neurological deficits, especially when located in eloquent brain regions. The eloquence of an AVM location is a critical factor in the treatment planning, influencing both the risk of complications and long-term functional outcomes. This study aims to compare outcomes between eloquent and non-eloquent AVMs. Methods: This multicenter, retrospective study utilized data from the Multicenter International Study for Treatment of Brain AVMs (MISTA) consortium. Patients with eloquent and non-eloquent AVMs were compared on baseline characteristics, angiographic outcomes, and functional outcomes using the modified Rankin Scale (mRS). Propensity score weighting (IPTW) was applied to adjust for confounding variables. Results: The study included 1013 patients, with 498 (49.2%) AVMs located in eloquent regions and 515 (50.8%) in non-eloquent regions. In unadjusted analysis, eloquent AVMs had lower complete obliteration rates (67.6% vs 79.5%, OR: 0.53, 95% CI: 0.39–0.72, p < 0.001) and higher complication rates (24.5% vs 19.0%, OR: 1.38, 95% CI: 1.02–1.86, p = 0.03) compared to non-eloquent AVMs. After IPTW adjustment, eloquent AVMs continued to show significantly higher odds of overall complications (OR: 1.68, 95% CI: 1.12–2.52, p = 0.01) and symptomatic complications (OR: 1.77, 95% CI: 1.12–2.80, p = 0.01). Secondary analysis within the eloquent group indicated that embolization was linked to an elevated risk of complications. Surgery and radiosurgery showed comparable functional outcomes at last follow-up and complications rates with higher complete obliteration rates in surgery. Conclusion: AVMs in eloquent brain areas present higher risks of complications and lower obliteration rates, emphasizing the need for cautious, individualized treatment planning. Within the eloquent group, embolization increased the risk of complications, while surgery and radiosurgery showed comparable functional outcomes at last follow-up and complication rates with higher complete obliteration rates in surgery. These findings highlight the importance of location in AVM management and support further research focusing on comparing treatment strategies for AVMs in eloquent brain areas.
Enhanced Functionality Using a Powered Upper Extremity Exoskeleton in Patients With Brachial Plexus Injuries
Bhat, Sandesh G. , Miller, Emily J. , Kane, Paul H., Hollander, Kevin W., Vignola, Claudio, Sugar, Thomas G. , Bhat, Sandesh G , Shin, Alexander Y. , Kaufman, Kenton R.

Mayo Clinic

IEEE Transactions on Neural Systems and Rehabilitation Engineering | February 13, 2025 | Volume: 33 | Issue: No issue available | Pages: 780-786

10.1109/tnsre.2025.3538175 | PMID 40031851 Get It

Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
Shi, Qian , Paiva, Bruno , Pederson, Levi , Dimier, Natalie , Talpes, Ela, Prior, Thomas J. , Órfão, Alberto , Sonneveld, Pieter , Kumar, Shaji , Patel, Reshma, Bartlett, Blake, Schecter, Jordan M. , Seckinger, Anja , D’Agostino, Mattia , Goldschmidt, Hartmut , Owen, Roger G., Durie, Brian G.M. , Munshi, Nikhil C. , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM), Pederson, Levi D , Moreau, Philippe , Sonneveld, Pieter , Kumar, Shaji K , Dixon, Jesse G. , McCarthy, Phillip , Hose, Dirk , Seckinger, Anja , Mattia, D'Agostino , Goldschmidt, Hartmut , Oliva, Stefania , Anderson, Kenneth C , San-Miguel, Jesus , Munshi, Nikhil C , Shi, Qian , Paiva, Bruno , Orfao, Alberto , Moreau, Philippe , Patel, Reshma, McCarthy, Philip L. , Hose, Dirk , Oliva, Stefania , Anderson, Kenneth C. , Miguel, Jesús F. San , Group, on behalf of the International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM)

Mayo Clinic

Journal of Clinical Oncology | February 12, 2025 | Volume: 43 | Issue: 11 | Pages: 1289-1301

10.1200/jco-24-02020 | PMID 39938021 Get It

PURPOSE Newly approved drugs and combinations treating multiple myeloma (MM) have resulted in substantial improvements in patients' survival. To deliver rapid access to newer therapies, an earlier end point to expedite clinical trials is needed. Our objective was to evaluate the minimal residual disease–negative complete response (MRD-CR) as an intermediate end point for progression-free survival (PFS) and overall survival (OS) in newly diagnosed (ND) transplant-eligible (NDTE) patients, ND transplant-ineligible (NDTinE) patients, and patients with relapsed/refractory (RR) MM. PATIENTS AND METHODS Individual patient data from 20 randomized multicenter trials were collected. Eleven studies (4,773 patients) with sufficient data were analyzed to evaluate whether 9- or 12-month MRD-CR classified at a 10 –5 threshold could be reasonably likely to predict the clinical benefit of new agents regarding PFS and OS. Global odds ratio (OR) was estimated using the bivariate Plackett Copula model. Supportive evaluation included correlations of the treatment effects on MRD-CR end points and PFS/OS, evaluated by both linear regression ( R 2 weighted least squared ) and Copula ( R 2 Copula ) models. RESULTS The analysis demonstrated that both 9- and 12-month MRD-CR strongly correlated with PFS at patient level in NDTE patients, NDTinE patients, and patients with RRMM. Global ORs ranged from 3.06 to 16.24, all with 95% CIs excluding 1.0. Encouraging trial-level correlations ( R 2 , 0.61-0.70) were observed by pooling three populations and were stronger ( R 2 , 0.67-0.78) in the ND population. Similar results were observed for OS. CONCLUSION Our findings provided the support for use of MRD-CR classified at a 10 –5 threshold at either 9 or 12 months after starting of the treatment, as an intermediate end point to support accelerated approvals, in future trials in NDTE patients, NDTinE patients, and patients with RRMM.
Psychological Distress and Quality of Life in Families With a Germline CDKN2A Pathogenic Variant
Onnekink, Anke , Klatte, Derk C.F. , Hooft, Jeanin E. van , Berg, S. H. van den, Zwaan, S. M. S. van der, Potjer, Thomas P. , Bleiker, Eveline M. A. , Onnekink, A M , Klatte, D C F , van Hooft, Jeanin E , Doorn, Remco van , Hinnen, Chris , Leerdam, Monique E. van

Mayo Clinic

Molecular Genetics & Genomic Medicine | February 12, 2025 | Volume: 13 | Issue: 2 | Pages: No page available

10.1002/mgg3.70045 | PMID 39936490 Get It

ABSTRACTBackgroundIndividuals with a germline CDKN2A pathogenic variant (PV) have an increased lifetime risk of melanoma and pancreatic cancer. It is unknown whether the CDKN2A PV impacts quality of life (QoL). Therefore we aimed to assess QoL and psychological distress in families affected by the PV.MethodsThis cross‐sectional study included confirmed carriers and those with a 50% likelihood of carrying the PV (at‐risk carriers) under cancer surveillance who were invited to complete a one‐time questionnaire. Both confirmed and at‐risk carriers are offered skin surveillance, whereas only confirmed carriers aged 40 years or older can participate in pancreatic surveillance.ResultsIn total, 59/247 (24%) individuals under skin surveillance only (skin surveillance group) and 188/290 (65%) individuals under both skin and pancreatic cancer surveillance (pancreatic surveillance group) responded. In both surveillance groups, health‐related QoL and general distress levels were within the general population norms. However, more than 40% of all study participants reported melanoma‐related distress. Pancreatic cancer‐related distress was experienced by 45% of the pancreatic surveillance group. Determinants of cancer‐related distress were a first‐degree relative with melanoma or pancreatic cancer, increased cancer risk perception, and poor general health perception. Over 80% of the participants felt that the benefits of cancer surveillance outweigh the disadvantages.ConclusionIn conclusion, confirmed and at‐risk carriers of the CDKN2A PV under cancer surveillance experienced similar levels of QoL and general distress compared to the general population. However, cancer‐related worry was substantial in this population. These findings can help identify individuals who may benefit from psychological support.
NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Pfister, David G. , Spencer, Sharon A., Adkins, Douglas, Birkeland, Andrew C. , Busse, Paul M., Durm, Greg Andrew , Fakhry, Carole , Galloway, Thomas J. , Geiger, J.L. , Gillison, Maura L. , Haddad, Robert I. , Hitchcock, Ying J. , Jimeno, Antonio , Leizman, Debra S., Maghami, Ellie, Mell, Loren K. , Pinto, Harlan A. , Price, Katharine A. , Rocco, James W. , Rodriguez, Cristina P. , Sher, David J. , Wang, He , Weinstein, Gregory S., Yom, Sue S. , Zhen, Weining, Darlow, Susan, Price, Katharine, Haddad, Robert , Yom, Sue S , Colevas, Alexander Dimitrios , Cmelak, Anthony J. , Adkins, Douglas, Brizel, David M. , Caudell, Jimmy J , Glastonbury, Christine M. , Hicks, Wesley L. , Juloori, Aditya , Kase, Michael, Mittal, Bharat B. , Schwartz, David A. , Shah, Jatin P. , John, Maie A. St. , Worden, Francis P. , Bruce, Justine Y. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 12, 2025 | Volume: 23 | Issue: 2 | Pages: 2-11

10.6004/jnccn.2025.0007 | PMID 39938471 Get It

The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of disease, stage, and pathologic findings guide treatment (eg, the appropriate surgical procedure, radiation targets, dose and fractionation of radiation, indications for systemic therapy). The NCCN Head and Neck Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding management of nasopharynx cancer and ongoing research in this area.
Addressing Spinal Implant Infections: Emerging Options and Unresolved Challenges
Tai, Don Bambino Geno , Patel, Robin , Lovecchio, Francis , Kwee, Thomas C. , Wouthuyzen‐Bakker, Marjan , Patel, Robin , Tai, Don Bambino Geno , Wouthuyzen-Bakker, Marjan

Mayo Clinic

Clinical Infectious Diseases | February 12, 2025 | Volume: 81 | Issue: 2 | Pages: e40-e40

10.1093/cid/ciaf065 | PMID 39935396 Get It

Optimal Timing of Primary Radiosurgical Treatment of Growing Vestibular Schwannoma: Insights From Salvage Microsurgery Outcomes
Marinelli, John P. , Herberg, Hans A., Moore, Lindsay S. , Kay‐Rivest, Emily , Casale, Garrett G. , Durham, Allison, Khandalavala, Karl R. , Lund‐Johansen, Morten , Kosaraju, Nikitha , Lohse, Christine M. , Patel, Neil S. , Babu, Seilesh C. , Golfinos, John G. , Kutz, Joe Walter , Maria, Peter L. Santa , Link, Michael J., Tveiten, Øystein Vesterli , Carlson, Matthew L. , Yancey, Kristen L. , Gurgel, Richard Klaus , Roland, J. Thomas , Hunter, Jacob B. , Link, Michael J.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 11, 2025 | Volume: 172 | Issue: 5 | Pages: 1717-1724

10.1002/ohn.1161 | PMID 39927827 Get It

AbstractObjectiveLimited evidence guides the optimal timing of treatment after the detection of tumor growth during the observation of sporadic vestibular schwannoma (VS). The current work aimed to inform the timing of radiosurgical intervention based on an analysis of patient outcomes among those who ultimately failed stereotactic radiosurgery (SRS) and underwent salvage microsurgery.Study DesignA historical cohort study.SettingSeven centers across the United States and Norway.MethodsAdults with sporadic VS who underwent salvage microsurgery following failed primary SRS were included. The primary outcome of interest was the association between tumor size at the time of primary SRS and the ability to achieve gross total resection (GTR) and maintain postoperative House–Brackmann (HB) facial nerve grade I at the last follow‐up after salvage microsurgery.ResultsAmong 96 patients, the median (interquartile range [IQR]) cerebellopontine angle (CPA) tumor size at primary SRS was 14.5 mm (10.0‐19.0). Each 1‐mm increase in CPA tumor size at the time of primary SRS was associated with a 13% increased likelihood of near‐total/subtotal resection or most recent postoperative HB grade >I (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.05‐1.21, P = .001), with an optimal tumor size threshold to distinguish this outcome of 12 mm of CPA extension (c‐index 0.73). Similarly, for each 1‐mm increase in CPA tumor size at the time of primary SRS, a 9% increase in any postoperative complication with salvage microsurgery was observed (OR 1.09, 95% CI 1.02‐1.15, P = .009).ConclusionCorroborated by size threshold surveillance data informing the timing of primary microsurgical resection, the current study suggests that VS outcomes are optimized when primary radiosurgical intervention is undertaken on growing tumors when they harbor 10–15 mm of cerebellopontine angle extension or less.
The influence of prestroke disability on outcome in patients with a low Alberta Stroke Program Early CT Score who underwent endovascular thrombectomy
Uchida, Kazutaka , Maier, Ilko , Jabbour, Pascal , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Mascitelli, Justin, Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Crosa, Roberto , Wolfe, Stacey Quintero , Fragata, Isabel , Matsukawa, Hidetoshi , Elawady, Sameh Samir , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Levitt, Michael R. , Moss, Mark, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Journal of Neurosurgery | February 7, 2025 | Volume: 143 | Issue: 1 | Pages: 266-273

10.3171/2024.10.jns24888 | PMID 39919282 Get It

OBJECTIVE The definitive influence of prestroke disability on outcomes in patients with a low Alberta Stroke Program Early CT Score (ASPECTS) treated with endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) due to large-vessel occlusion (LVO) remains unknown. This study aimed to investigate the impact of prestroke disability on outcomes in this specific population. METHODS Data from 32 international centers for AIS-LVO patients with a low ASPECTS who underwent EVT between January 2013 and December 2022 were analyzed retrospectively. Low ASPECTS and prestroke disability were defined as ASPECTS values of 2–5 and prestroke modified Rankin Scale (mRS) score ≥ 2. The primary outcome was a return to the prestroke mRS score at 90 days. Secondary outcomes were independent ambulation (mRS scores of 0–3) or a return to the prestroke mRS score at 90 days, good functional outcome (mRS scores of 0–2) or a return to the prestroke mRS score at 90 days, successful recanalization, and 90-day mortality. Safety outcomes were any intracranial hemorrhage or symptomatic intracranial hemorrhage. A symptomatic intracranial hemorrhage was defined as an intracranial hemorrhage with an associated worsening of ≥ 4 points in the National Institutes of Health Stroke Scale score. Outcomes were compared between patients with and without prestroke disability. RESULTS Of 293 patients, 50 (17.1%) had a prestroke disability. Of 50 patients, 20 (40.0%), 24 (48.0%), and 6 (12.0%) had prestroke mRS scores of 2, 3, and 4, respectively. The primary outcome showed no significant difference between the two groups. Compared with patients without prestroke disability, those with prestroke disability had a significantly smaller proportion of independent ambulation or return to prestroke mRS score (adjusted OR 0.13, 95% CI 0.03–0.53) and good functional outcome or return to prestroke mRS score (adjusted OR 0.21, 95% CI 0.05–0.91). Other secondary and safety outcomes showed no significant difference between the two groups. CONCLUSIONS The present study indicated that prestroke disability was not associated with a return to the prestroke mRS score at 90 days or intracranial hemorrhage. Physicians should not routinely exclude AIS-LVO patients with a low ASPECTS who have prestroke disability from EVT based on prestroke disability alone.